Zuellig Pharma’s Post

A couple of weeks ago, I had the pleasure to attend and speak at the Value-Based Health 2030 Conference in Tallinn. Talking about a digital health project like H2O in Estonia felt like preaching to the converted! This is probably one of the most advanced digitalized country in Europe – especially when it comes to healthcare. It was really interesting to hear about the OnContact project, a like-minded project they have been running in Estonia. And of course, listening to a great presentation by Francesca Colombo from the OECD - OCDE on why #VBHC matters to healthcare systems and how digital technologies can be the catalyst, puts it all in a different context. These are not just projects, we need to find a way to connect the dots and make our joint vision of patient centered care a reality for patients across the globe. Helis Pokker Francesca Colombo European Alliance for Value in Health EFPIA - European Federation of Pharmaceutical Industries and Associations

🎙️ I had the privilege of joining Lesley Regan, Ben Lucas and Dr Nikita Kanani MBE for a panel on the future of #women’shealth. What struck me most was the power of combining research, clinical expertise, and industry innovation to tackle the biggest challenges we face. We discussed how cross-sector collaboration is the key to unlocking advancements in the healthcare of women, raising standards and improving outcomes. And whilst there’s still a long way to go, these conversations are a crucial step in building a future where women’s health is finally prioritized. What's your biggest hope for the future of women's health? 💬 #WomensHealth #HealthcareInnovation #Collaboration #womensresearch #genderhealthgap #nhs

Today, I am delighted to share an insightful article from ETHealthWorld featuring an interview with Dr. Rajendra Pratap Gupta, PhD, a distinguished Council member of the Global Health Connector Partnership. Dr. Rajendra Pratap Gupta, PhD, clearly states, "Digital health isn't just a cost; it's a strategic asset that transforms healthcare delivery and financial models." He highlights that by 2025, it will be essential for all healthcare sectors, from doctors to pharmaceutical companies, to integrate digital tools to stay relevant and competitive. This shift towards digital innovation promises to significantly enhance the efficiency and quality of patient care, turning digital health into a valuable profit centre rather than just a cost. It’s an exciting time for the industry, and this interview illustrates why embracing digital health is so vital for our future. Read the full article here: https://lnkd.in/e89i53ED #DigitalHealth #HealthcareInnovation #FutureOfHealthcare #HealthTech #GlobalHealth #MedTech #HealthTransformation #ETHealthWorld

This is a timely post with the Digital Health Festival currently taking place in Melbourne. How can digital health companies use Real World Evidence to enhance their clinical impact and outcomes, regulatory submissions and commercialisation? Insight brief below. IQVIA MedTech #realworldevidence #digitalhealth

🌟 Thrilled to announce that Vitaccess has joined the DEEP Measures ecosystem! 🌟 DEEP is dedicated to building digital measures of health, unlocking insights into human health by simplifying the complex process of developing and validating these measures - from definition to regulatory acceptance. As a member of this innovative community, Vitaccess is thrilled to bring our expertise in real-world evidence generation to support the validation of digital health measures. Together, we’ll help ensure these tools are reliable, impactful, and ready to advance drug development and patient care. Joining the DEEP Ecosystem opens up opportunities for collaboration with leading organizations in digital health innovation. As a group we aim to ensure that digital measures are rigorously tested, reliable, and impactful for patients and healthcare providers alike. We can’t wait to share updates on how this partnership will help shape the future of digital health evidence. Let’s drive meaningful change - together!

Unlocking the potential of Digital Health with Real-World Evidence (RWE) is more than a trend—it's a transformation. In our latest Insight Brief, experts Brinda Sriskantha, Michelle Bulliard, Nick Mageras, and Oliver Bailey explore the crucial role of RWE across the digital health product lifecycle. From regulatory challenges to market strategies, this insights brief outlines how digital health is not just supporting, but revolutionizing patient care. Key takeaways include: 1. The pivotal role of RWE in supporting regulatory and payer decision-making. 2. Strategies for the effective commercialization of digital health solutions. 3. Real-world applications of digital health innovations, accelerating patient-centric care outside traditional settings. As we navigate the digital revolution, how can Pharma and MedTech leverage these insights to enhance patient outcomes and optimize digital health technologies? What challenges have you faced in integrating digital health into your business model? Let’s discuss and drive the future of healthcare innovation forward together! #DigitalHealth #RealWorldEvidence #Pharma #MedTech #HealthcareInnovation #IQVIA

We have just released our latest Insight Brief on Advancing Digital Health Innovation using Real World Evidence! Check it out below. Thanks for sharing Brian Lovinguth!

Yesterday we co-hosted with HealthXL a roundtable on the beliefs and behaviours that are holding digital health back. The topics we covered were far reaching, from: 💡 What our most unhelpful beliefs are - organisationally, culturally, commercially - that are stalling digital health in pharma?  💡 What helpful beliefs exist - typically rooted in the true digital health champions and strategists? 💡 What is the real value of digital health in pharma and how do we define it? 💡 Where does it make sense for pharma companies to place their bets? Thank you to Rafael Lira Carrillo from Merz Therapeutics, Spencer J. from Bristol Myers Squibb, Keith Ho from Jazz Pharmaceuticals, Arndt A. Schmitz from Bayer, Michael Kremliovsky from Bayer, Christy Cheung from Sanofi, Caroline Gosling and Harry Malcolm from Rubica Change & Analytics for Life Sciences, Tessy Huss from HealthXL for being part of the conversation. Watch this space as we’ll be writing an article about what we’ve uncovered and how you can work with beliefs and behaviours to advance digital health in your own organisation. For now, we'll leave you with our favourite quote from the session “if you want to get people onboard with digital health, you’ve got to be a fixer first”! #DigitalHealth #HealthTech #LimitingBeliefs #EmpoweringBeliefs #BehaviourChange  

Giovanny Leon opens day two at Pharma 2024 with a case study presentation that uncovers the critical factors influencing patient access and explores data-driven insights that highlight the varying impacts on individuals across different socioeconomic backgrounds. Giovanny addresses the power of adopting a Patient-Centric Commercialization mindset and discusses how this approach can effectively bridge the gaps in healthcare accessibility and affordability, creating a more inclusive healthcare environment for all. #REpharma2024

Engaging discussions on day 1 at the Reuters event Pharma 2024 in Barcelona today. Key themes revolved around equity in healthcare access and sustainability. Stefan Oelrich kickstarted the day questioning the feasibility of funding innovative treatments for diseases like Alzheimer’s or Parkinson’s. Later, Monica Shaw highlighted the stable healthcare budget allocation at 15%, despite significant innovation waves. This challenges the misconception that drug costs solely drive healthcare access and equity issues. As we navigate these complexities, how do we strike a balance for equitable healthcare access, acknowledging the industry's contributions to society and healthcare beyond just drug costs? #REPharma2024 #HealthcareEquity #Sustainability